Panlong Pharmaceutical Industry: Cancellation of the dedicated account for fundraising for traditional Chinese medicine projects.

Panlong Pharmaceutical announced that in September 2023, the company issued 9.3527 million shares to specific investors at a price of 32.29 yuan per share, raising a total of 302 million yuan, with a net amount of 295 million yuan. The company had previously signed a "Three-party Supervision Agreement for Fundraising" with the sponsoring institution and related banks. As of the date of the announcement, the account at the Xi'an Software Park branch of the Bank of China, used for the "Research and Industrialization Project of Traditional Chinese Medicine Granules Formulation", had a zero balance and was deregistered in 2026, resulting in the termination of the corresponding supervision agreement simultaneously.